TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10869913

Group type: EXPERIMENTAL
Intervention: Halothane anesthesia (G1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Opioid anesthesia (G2)
Number of subjects: 42
Study: 8924193

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 1531952

Group type: EXPERIMENTAL
Intervention: Zabicipril
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3891362

Group type: COMPARATOR
Intervention: Dihydroxybusulfan (B) 600 mg/m2 p.o. for 4-6 weeks q 12 weeks
Number of subjects: 156

Group type: COMPARATOR
Intervention: Cyclophosphamide (C) 150 mg/m2 p.o. for 7 days q 4 weeks
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: CAF (Cyclophosphamide 400 mg/m2 i.v., doxorubicin 30 mg/m2, 5-fluorouracil 400 mg/m2 i.v., days 1 and 8 q 4 weeks)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Pelvic irradiation (for stage IIB patients)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Second-look laparotomy
Number of subjects: 156
Study: 31584944

Group type: EXPERIMENTAL
Intervention: Wirelessly observed therapy (WOT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Directly observed therapy (DOT)
Number of subjects: 77
Study: 29904986

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 898

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Higher health literacy
Number of subjects: 898
Study: 26987589

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 70

Group type: COMPARATOR
Intervention: avastin
Number of subjects: 70
Study: 24502469

Group type: EXPERIMENTAL
Intervention: Referral to a specialist cardiometabolic health care nurse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialist cardiometabolic health care nurse
Number of subjects: 0
Study: 21898066

Group type: EXPERIMENTAL
Intervention: Therapeutic microwave diathermy (MD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham microwave diathermy (MD)
Number of subjects: 40
Study: 20551194

Group type: EXPERIMENTAL
Intervention: RCTs that mentioned adverse drug reactions (ADRs)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: RCTs that used standardised methods for disclosure of ADRs
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: RCTs that tabulated adverse drug reactions
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: RCTs that stated numbers of and reasons for withdrawal
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: RCTs that reported safety data adequately according to Consort guidelines
Number of subjects: 107

Group type: COMPARATOR
Intervention: Influence of registration on reporting
Number of subjects: 107

Group type: COMPARATOR
Intervention: Influence of sponsoring on reporting
Number of subjects: 107
Study: 17284729

Group type: EXPERIMENTAL
Intervention: Television watching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel food (French fries)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous television show
Number of subjects: 0

Group type: COMPARATOR
Intervention: No television
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated segment of a television show
Number of subjects: 0
Study: 16146472

Group type: EXPERIMENTAL
Intervention: Propofol/Ketamine (PK group)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Propofol/Alfentanil (PA group)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 276
Study: 14578018

Group type: EXPERIMENTAL
Intervention: Acupuncture (ear and body)
Number of subjects: 34
Study: 11246561

Group type: EXPERIMENTAL
Intervention: 5000 U TNF-alpha
Number of subjects: 8
Study: 9566100

Group type: EXPERIMENTAL
Intervention: H15 (3600 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: H15
Number of subjects: 37
Study: 7827399

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 microgram twice daily
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 to 1.0 micrograms/day plus calcium 1000 mg/day
Number of subjects: 622

Group type: COMPARATOR
Intervention: Elemental calcium 1000 mg/day
Number of subjects: 622
Study: 3137320

Group type: EXPERIMENTAL
Intervention: Low-volume enteral feeds (12 ml/kg/day) in addition to parenteral alimentation for 10 days starting on day 8 of life
Number of subjects: 46

Group type: COMPARATOR
Intervention: Parenteral alimentation alone until day 18 of life
Number of subjects: 46
Study: 30017510

Group type: EXPERIMENTAL
Intervention: Ankle–foot orthosis (AFO)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Laterally wedged shoes
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Conventional unloader brace
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (own shoes)
Number of subjects: 52
Study: 28095259

Group type: EXPERIMENTAL
Intervention: British Columbia Adult Mental Health Practice Support Program
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study: 26335904

Group type: EXPERIMENTAL
Intervention: Light sedation (BIS 70-80)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Deep sedation (BIS < 60)
Number of subjects: 200
Study: 23476752

Group type: EXPERIMENTAL
Intervention: Social support intervention with moderate-intensity physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Access to healthy food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio
Number of subjects: 0
Study: 21513604

Group type: EXPERIMENTAL
Intervention: Volume-targeted noninvasive ventilation (NIV)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pressure-targeted noninvasive ventilation (NIV)
Number of subjects: 16
Study: 18307077

Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraceptive pills (ECP), condoms, and an information leaflet
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 420
Study: 17139825

Group type: EXPERIMENTAL
Intervention: Surfactant inhalations (700 mg cumulative dose over 8 weeks) during chemotherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Chemotherapy only (control group)
Number of subjects: 140
Study: 12540551

Group type: EXPERIMENTAL
Intervention: Single nasal immunization with CRM197 in chitosan delivery system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second nasal immunization with CRM197 in chitosan delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intramuscular vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal immunization with CRM197 without chitosan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral intranasal immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second immunization
Number of subjects: 0
Study: 10890906

Group type: EXPERIMENTAL
Intervention: Three frequencies used in the first experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nine frequencies used in the second experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five frequencies used in the third experiment
Number of subjects: 0
Study: 8731520

Group type: EXPERIMENTAL
Intervention: 40 mg THA (tacrine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg THA (tacrine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1414965

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29706227

Group type: EXPERIMENTAL
Intervention: DMPA‐SC self‐injection
Number of subjects: 30
Study: 28514347

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment using ABO anthropometric system with indirect bonding
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional orthodontic treatment protocol
Number of subjects: 32
Study: 25560575

Group type: EXPERIMENTAL
Intervention: Dezocine 0.1mg/kg
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control (0.9% normal saline)
Number of subjects: 370
Study: 23621161

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 143

Group type: COMPARATOR
Intervention: mycophenolate
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: high-dose statins
Number of subjects: 143
Study: 20889053

Group type: EXPERIMENTAL
Intervention: Light-force chincup (125-250 g)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Quad-helix appliance with chincup
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chincup only
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated Class III)
Number of subjects: 26
Study: 19882741

Group type: EXPERIMENTAL
Intervention: Occupational health intervention program to reduce WBV exposure, implemented for 7 months.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Care-as-usual group (control group).
Number of subjects: 126
Study: 16782094

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15128463

Group type: EXPERIMENTAL
Intervention: Decision aid for antithrombotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 11740232

Group type: EXPERIMENTAL
Intervention: IGF-1 treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9006424

Group type: COMPARATOR
Intervention: Acetazolamide (Diamox)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride (Trusopt)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetazolamide added to dorzolamide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dorzolamide added to acetazolamide
Number of subjects: 40
Study: 8215566

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Plasma protein fraction
Number of subjects: 39
Study: 3321873

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Combination of amniotomy and oxytocin
Number of subjects: 223

Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Amniotomy added to oxytocin
Number of subjects: 223

Group type: COMPARATOR
Intervention: Bishop score
Number of subjects: 223
Study: 28632915

Group type: EXPERIMENTAL
Intervention: WCRF‐NL health promotion materials
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study: 27535127

Group type: EXPERIMENTAL
Intervention: Soybean oil-based mayonnaise (SB-mayo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palm olein-based mayonnaise (PO-mayo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both SB-mayo and PO-mayo
Number of subjects: 0
Study: 25062801

Group type: EXPERIMENTAL
Intervention: Tools for Getting Along (TFGA) curriculum
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 720
Study: 22905823

Group type: EXPERIMENTAL
Intervention: Increased VSTM load (manipulated by increased set size)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual detection experiments
Number of subjects: 0
Study: 21118617

Group type: EXPERIMENTAL
Intervention: Mixed n‐3/n‐6 PUFA diets
Number of subjects: 8

Group type: COMPARATOR
Intervention: n‐6 specific PUFA diets
Number of subjects: 8

Group type: COMPARATOR
Intervention: RCT substituting n‐6 PUFA for TFA and SFA without increasing n‐3 PUFA
Number of subjects: 8
Study: 18521101

Group type: EXPERIMENTAL
Intervention: 16 gauge needles
Number of subjects: 204

Group type: COMPARATOR
Intervention: 18 gauge needles
Number of subjects: 204
Study: 15994254

Group type: EXPERIMENTAL
Intervention: PR‐SHAM
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PR‐IMT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 12812678

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) solution
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 10566563

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 10 days)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 10 days)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 542

Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 542
Study: 8912230

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: paroxetine (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ipsapirone (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1841020

Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Maintenance nifedipine therapy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 4
Study: 6356628

Group type: EXPERIMENTAL
Intervention: 75 mg pirlindol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 150 mg pirlindol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 225 mg pirlindol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 mg imipramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg tranylcypromine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 150 mg nomifensine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31050161

Group type: EXPERIMENTAL
Intervention: liraglutide-metformin
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo-metformin
Number of subjects: 41
Study: 28673277

Group type: EXPERIMENTAL
Intervention: Protein-based assay with a 15-min webinar
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no assay results)
Number of subjects: 129
Study: 25697725

Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 497
Study: 23538170

Group type: EXPERIMENTAL
Intervention: MABA 400 μg once daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MABA 1200 μg once daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TIO + SAL (tiotropium 18 μg once daily plus salmeterol 50 μg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21434341

Group type: EXPERIMENTAL
Intervention: Yishen Jiangzhuo Granule (YJG)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 19551272

Group type: EXPERIMENTAL
Intervention: 2 alternate daily preprandial measurements
Number of subjects: 21

Group type: COMPARATOR
Intervention: 2 alternate daily pre‐ and postprandial measurements
Number of subjects: 21
Study: 17537842

Group type: EXPERIMENTAL
Intervention: GHRP-2 (a ghrelin analog)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant GHRP-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constant GHRH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 0
Study: 12811566

Group type: EXPERIMENTAL
Intervention: IT(100%) - Intermittent training at 100% of vVO(2max)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: IT(105%) - Intermittent training at 105% of vVO(2max)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Incremental test
Number of subjects: 7
Study: 11153582

Group type: EXPERIMENTAL
Intervention: Nebuchamber (metal spacer) with Budesonide (200 microg b.i.d)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: nonDC-Babyhaler (detergent coated plastic spacer) with Fluticasone (125 microg b.i.d)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DC-Babyhaler (non-detergent coated plastic spacer) with Fluticasone (125 microg b.i.d)
Number of subjects: 25
Study: 9094151

Group type: EXPERIMENTAL
Intervention: Loxiglumide (2.4 g/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Surgical palliation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 64
Study: 8249952

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.3 to 0.4 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3510088

Group type: EXPERIMENTAL
Intervention: 40 min of bicycling three times per week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 min of bicycling seven times per week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Below-sedentary activity
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 12
Study: 31470735

Group type: EXPERIMENTAL
Intervention: 24-week online training program coupled with a physician engagement strategy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 24-week online training program
Number of subjects: 63
Study: 30054920

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/d
Number of subjects: 139

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg/d
Number of subjects: 139

Group type: COMPARATOR
Intervention: Linagliptin 5 mg/d
Number of subjects: 139
Study: 27299900

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 10
Study: 25223724

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 52 weeks (group A)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 4 weeks and then 150 mg once daily (group B)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Placebo for 24 weeks (group C)
Number of subjects: 918
Study: 22396087

Group type: EXPERIMENTAL
Intervention: Validation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Invalidation
Number of subjects: 50
Study: 20200257

Group type: EXPERIMENTAL
Intervention: 3 g/d of 80% CLA (50:50 cis-9,trans-11 and trans-10,cis-12 isomers)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 3 g/d of 80% CLA
Number of subjects: 62
Study: 18519483

Group type: EXPERIMENTAL
Intervention: Supplementation with 32 mg of docosahexaenoic acid and 31 mg of arachidonic acid per 100 mL of human milk
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Supplementation with docosahexaenoic acid and arachidonic acid
Number of subjects: 141
Study: 16402647

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg
Number of subjects: 4924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4924

Group type: COMPARATOR
Intervention: Loratadine, 10 mg
Number of subjects: 4924
Study: 12415411

Group type: EXPERIMENTAL
Intervention: Tissue adhesive 2-octylcyanoacrylate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 59
Study: 9892301

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 83
Study: 8896010

Group type: EXPERIMENTAL
Intervention: Combined epidural/general anesthesia (CEGA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 40
Study: 1758241

Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 20% of control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 40% of control (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 60% of control (Group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 80% of control (Group IV)
Number of subjects: 40
Study: 6177407

Group type: EXPERIMENTAL
Intervention: CHOP-B
Number of subjects: 29

Group type: COMPARATOR
Intervention: ACOMLA
Number of subjects: 29
Study: 31872906

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional statin therapy
Number of subjects: 66
Study: 30616597

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study: 27804174

Group type: EXPERIMENTAL
Intervention: Once-daily treatment for asthma and COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of multiple data sources
Number of subjects: 0
Study: 26025795

Group type: EXPERIMENTAL
Intervention: 15-minute hand massage
Number of subjects: 40

Group type: COMPARATOR
Intervention: 15-minute hand-holding without massage (Control)
Number of subjects: 40
Study: 24450370

Group type: EXPERIMENTAL
Intervention: Exercise intervention (MDT directional exercises for knee derangements and evidence-based exercises for nonresponders)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 180
Study: 22485049

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 0
Study: 20848639

Group type: EXPERIMENTAL
Intervention: Double Pulse (DP) mode
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard Single Pulse (SSP) mode
Number of subjects: 11
Study: 17931064

Group type: EXPERIMENTAL
Intervention: Relaxation response (RR) tapes and soft music during acupuncture treatment; RR tapes listened to at home daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Soft music during acupuncture treatment (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Relaxation response (RR) tapes and soft music during acupuncture treatment
Number of subjects: 80
Study: 16087945

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U once weekly for 12 months
Number of subjects: 939

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939